Navigation Links
Abbott's XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award
Date:10/28/2008

Fourth Innovation Award for Abbott in Six Years Recognizes Breakthrough

Treatment for the Most Common Form of Heart Disease

ABBOTT PARK, Ill., Oct. 28 /PRNewswire/ -- Abbott today announced it has received a 2008 Chicago Innovation Award for its XIENCE V(TM) Everolimus Eluting Coronary Stent System. Based on the product's innovative design and strong clinical data, the next-generation drug eluting stent represents a significant advance in the treatment of coronary artery disease.

Abbott's XIENCE V stent was approved by the United States Food and Drug Administration (FDA) and launched in July 2008, providing a new treatment option for the nearly 13 million Americans with coronary artery disease, the leading cause of death for both men and women in the United States. Stents are designed to prop open an artery that has become clogged by plaque build-up and restore blood flow to the heart. A drug eluting stent releases a medication (everolimus, in the case of XIENCE V) in a controlled manner to prevent the artery from becoming blocked again following a stent procedure. XIENCE V is the only drug eluting stent to demonstrate superiority over the previous market-leading drug eluting stent in two randomized, pivotal clinical trials -- and XIENCE V has become the market-leading drug eluting stent in just three months since launch.

This is the fourth Chicago Innovation Award that Abbott has received in six years. Most recently, the company's m2000(TM) molecular diagnostic instrument in combination with the RealTime HIV-1 viral load test received the honor in 2007. In 2005, the company's PathVysion(TM) breast cancer test received the honor, and in 2003, HUMIRA(TM), the first human monoclonal antibody drug for rheumatoid arthritis, won the award.

"At Abbott, we are proud to be in the business of developing innovative treatments that improve and save lives," said Miles D. White, chairman and chief executive officer, Abbott. "Receivi
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
2. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
3. Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
4. Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
5. Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels
6. Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
7. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
8. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
9. Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
10. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
11. PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)..., LYNBROOK, N.Y., Nov. 6 /PRNewswire-FirstCall/ ...), a biopharmaceutical company developing first-in... its financial results for the third quarter ended...py that, in September of this year, the FDA,s Arth...by a vote of 12-0, the approval of XIAFLEX(TM) for...
(Date:11/6/2009)..., SPRING VALLEY, Calif., Nov. 6 ...awarded a Small Business Innovative Research (SBIR...ch and Material command. Under terms of the agreem...ents (ASRs) for the diagnosis of Dengue virus. ...hat represents a major threat to military forces d...
(Date:11/5/2009)..., GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstCal...d its financial results for the third quarter ende...f $3.6 million ($0.04 per share) for the three mon...s of $6.8 million ($0.08 per share) in the compara...tember 30, 2009, GenVec,s net loss was $14.1 milli...
(Date:11/5/2009)..., Conference Call on Thursday, November 5, 2009 ...ANCOUVER Nov. 5 /PRNewswire-FirstCall/ - OncoGenex...y") (NASDAQ: OGXI ) today reported unaudited fina...s ended September 30, 2009 and reviewed the Compan..., The following consolidated results reflect the o...
Breaking Biology Technology:Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8
...Premier Award Program for,Medical Technology, COL...lle, the world,s largest non-profit independent re...ed the winning of a Medical Design,Excellence Awar...ctor, a,technology that enhances the safety of con...xtravasations. Extravasation is leakage of fluid,i...
...dicare Policy, SAN CARLOS, Calif., April 8, 2008 ...MS) have approved at-home sleep testing,for obstru...ted that,suspected sleep apnea sufferers undergo f...ws continuous positive airway pressure (CPAP) trea...unattended home monitoring devices.,This decision ...
.... Fresne,Chairman and CEO, Egenix, Inc., announced...n of the company,s scientific advisory board. Dr.,...ine at Columbia,University Medical Center where he... Medical Oncology. He is the co-author of numerous... leader in the treatment of cancers of,prostate, k...
Other Biology Technology:MEDRAD, Battelle Win Medical Design Excellence Award for MEDRAD XDS(TM) Extravasation Detector 2Medicare Approves in Home Sleep Apnea Testing 2
(Date:11/6/2009)...LPHIA (November 06, 2009) The Monell Center and t...of the Beijing International Meeting on Taste and ...on with the CAS, the meeting will be the first int...n China. , Alan Leshner, Chief Executive Officer...nce and Executive Publisher of Science magazine, w...
(Date:11/4/2009)...S: (top news in natural science) , United Stat...ses less water today than it did 35 years ago, des... water use are partly attributable to alternative ... irrigation systems. According to the latest USGS ... the United States goes to cooling thermoelectric ...
(Date:11/4/2009)...versity of Oklahoma at Norman has received more th...g agencies as part of the federal stimulus program...eived by OU researchers to $23 million. Thirty-th... ranging from archaeology to weather. , "The uni...pproach to matching areasof scholarly excellence t...
Breaking Biology News(10 mins):Monell Center joins with CAS to host Beijing meeting on taste and smell research 2USGS science picks 2USGS science picks 3USGS science picks 4USGS science picks 5USGS science picks 6USGS science picks 7OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3BioSpace Launches the 2010 Biotech Beach Hotbed Campaign 58625 1BioSpace Launches the 2010 Biotech Beach Hotbed Campaign 58625 2OAKWORKS Clinician Massage Table Product Line Gets a Green Makeover 58621 1OAKWORKS Clinician Massage Table Product Line Gets a Green Makeover 58621 2OAKWORKS Clinician Massage Table Product Line Gets a Green Makeover 58621 3OAKWORKS Clinician Massage Table Product Line Gets a Green Makeover 58621 4OAKWORKS Clinician Massage Table Product Line Gets a Green Makeover 58621 5CMS Approves Press Ganey as a Qualified Home Health Care CAHPS Survey Vendor 58617 1CMS Approves Press Ganey as a Qualified Home Health Care CAHPS Survey Vendor 58617 2CMS Approves Press Ganey as a Qualified Home Health Care CAHPS Survey Vendor 58617 3
...oastal management practices are ineffective and th... the economies on which over half the worlds popul...rn in a new report offering a major prescription f...e presented Weds. June 4 at UN Headquarters, New Y...Water, Environment and Health warns of a looming, ...
...g, Va. Researchers at the Virginia Bioinformatics...l Disease Center in Ames, Iowa, and collaborators ...enced the genome of Brucella abortus strain S19.... abortus that does not cause disease and was disc...for more than six decades as vaccine that protects...
...rs of Northeastern offshore spotted and eastern sp...an are increasing after being severely depleted be...fishery between 1960 and 1990, according to biolog...imates are encouraging because they are consistent...are recovering, now that reported fishery mortalit...
Other Biology News:Coastal management cooperation, enforcement key to avoid pending crisis for millions: UN experts 2Coastal management cooperation, enforcement key to avoid pending crisis for millions: UN experts 3Coastal management cooperation, enforcement key to avoid pending crisis for millions: UN experts 4Coastal management cooperation, enforcement key to avoid pending crisis for millions: UN experts 5Coastal management cooperation, enforcement key to avoid pending crisis for millions: UN experts 6Brucella abortus S19 genome sequenced; points toward virulence genes 2NOAA study shows eastern tropical pacific ocean dolphin populations improving 2
HeLa Cell Slide from ProSci, Inc
EL4 Cell Slide from ProSci, Inc
IHC Select TE Buffer pH 9.0 [Antigen/ Epitope Retrieval Reagent], 10x from CHEMICON
Hep G2 Cell Slide from ProSci, Inc
Biology Products: